End of the road for daclizumab in multiple sclerosis

Lancet. 2018 Mar 17;391(10125):1000. doi: 10.1016/S0140-6736(18)30565-8. Epub 2018 Mar 15.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Daclizumab
  • Drug Recalls*
  • Humans
  • Immunoglobulin G / therapeutic use*
  • Immunosuppressive Agents / therapeutic use*
  • Multiple Sclerosis / drug therapy*

Substances

  • Antibodies, Monoclonal, Humanized
  • Immunoglobulin G
  • Immunosuppressive Agents
  • Daclizumab